Read by QxMD icon Read

Urologic Oncology

Saum Ghodoussipour, Siamak Daneshmand
Significant evidence exists regarding the diagnostic and therapeutic roles of pelvic lymph node dissection at the time of radical cystectomy for patients with bladder cancer. Despite this, lymphadenectomy for bladder cancer is still underutilized and even where performed, controversies exist in regard to what defines an adequate dissection and whether or not the indications for lymphadenectomy have changed now that we are firmly entrenched in the neoadjuvant chemotherapy era. A comprehensive literature review was performed to touch on these important issues and highlight future directions and current trials that will soon provide more clarity for surgeons and patients dealing with bladder cancer...
June 14, 2018: Urologic Oncology
Shengmeng Peng, Tao Du, Wanhua Wu, Xianju Chen, Yiming Lai, Dingjun Zhu, Qiong Wang, Xiaoming Ma, Chunhao Lin, Zean Li, Zhenghui Guo, Hai Huang
PURPOSE: The aim of this study was to investigate the associations of serine proteinase inhibitor family G1 (SERPING1) down-regulation with poor prognosis in patients with prostate cancer (PCa). Furthermore, we aim to find more novel and effective PCa molecular markers to provide an early screening of PCa, distinguish patients with aggressive PCa, predict the prognosis, or reduce the economic burden of PCa. METHODS: SERPING1 protein expression in both human PCa and normal prostate tissues was detected by immunohistochemical staining, which intensity was analyzed in association with clinical pathological parameters such Gleason score, pathological grade, clinical stage, tumor stage, lymph node metastasis, and distant metastasis...
June 11, 2018: Urologic Oncology
Jonathan J Aning, Kenneth R MacKenzie, Michael Fabricius, Elaine McColl, Mark I Johnson, Zafer Tandogdu, Naeem A Soomro, Christopher Harding
OBJECTIVE: To prospectively evaluate short- to medium-term patient-reported lower urinary tract symptoms (LUTS) and their effect on health-related quality of life (HRQoL) using validated questionnaires in a large cohort of patients following robotic-assisted radical prostatectomy (RARP) for prostate cancer. MATERIALS AND METHODS: HRQoL and LUTS outcomes were prospectively assessed in 357 consecutive men undergoing RARP at a single center from 2012 to 2015 using the functional assessment of cancer therapy-prostate (FACT-P) and the international consultation on incontinence modular questionnaire-male LUTS (ICIQ-MLUTS)...
June 9, 2018: Urologic Oncology
Kiarash Taghavi
No abstract text is available yet for this article.
June 8, 2018: Urologic Oncology
Kimberly A Maciolek, Sara L Best, Vania Lopez, Natasza Posielski, Margaret Knoedler, Wade A Bushman, David F Jarrard, Tracy M Downs, E Jason Abel, Kyle A Richards
PURPOSE: To prospectively implement a prostate biopsy protocol to identify high-risk patients for bleeding or infectious complications and use risk-tailored antimicrobials, patient education, and postbiopsy monitoring with the objective of reducing complications. MATERIALS AND METHODS: Overall, 637 consecutive patients from June 2014 to August 2016 underwent prostate biopsy at our Veterans Affairs hospital. In the protocol cohort, patients were screened before biopsy and prophylaxis was tailored (high risk = ceftriaxone; low risk = ciprofloxacin)...
June 7, 2018: Urologic Oncology
Felix Preisser, Sebastiano Nazzani, Marco Bandini, Michele Marchioni, Zhe Tian, Francesco Montorsi, Fred Saad, Alberto Briganti, Thomas Steuber, Lars Budäus, Hartwig Huland, Markus Graefen, Derya Tilki, Pierre I Karakiewicz
OBJECTIVES: To investigate lymph node invasion (LNI) rates in prostate cancer (PCa) patients. Recent studies demonstrated an inverse stage migration in PCa patients toward more advanced and unfavorable diseases. We hypothesized that this trend is also evident in LNI rates, in PCa patients treated with radical prostatectomy (RP) and pelvic lymph node dissection (PLND). PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2014), we identified patients who underwent RP and PLND...
June 7, 2018: Urologic Oncology
Shalini S Yadav, Jennifer A Stockert, Victoria Hackert, Kamlesh K Yadav, Ashutosh K Tewari
Prostate cancer (PCa) has long been thought of as a disease with a heterogeneous phenotype. It can manifest in men as benign growths that can be safely watched or as more aggressive malignancies that can prove fatal. Recent investigations at the genomic, histopathological and molecular levels have identified tumor heterogeneity, the phenomenon of individual tumor cells presenting distinct genomic and phenotypic characteristics, as one of the most confounding and complex factors underlying PCa diagnosis, prognosis, and treatment...
June 7, 2018: Urologic Oncology
Liam C Macleod, Robert M Turner, Samia Lopa, Lee A Hugar, Benjamin J Davies, Bruce Ben-David, Jacques E Chelly, Bruce L Jacobs, Joel B Nelson
BACKGROUND: Recent studies suggest that anesthetic technique during radical prostatectomy for prostate cancer may affect recurrence or progression. This association has previously been investigated in series that employ epidural analgesia. The objective of this study is to determine the association between the use of a multimodal analgesic approach incorporating paravertebral blocks and risk of biochemical recurrence following open radical prostatectomy. PATIENTS AND METHODS: Using a prospective database of 3,029 men undergoing open radical prostatectomy by a single surgeon, we identified 2,909 men who received no neoadjuvant androgen deprivation and had at least 1 year of follow up...
June 7, 2018: Urologic Oncology
Carine Pecqueux, Aysenur Arslan, Martina Heller, Michael Falkenstein, Adam Kaczorowski, Yanis Tolstov, Holger Sültmann, Carsten Grüllich, Esther Herpel, Anette Duensing, Glen Kristiansen, Markus Hohenfellner, Nora M Navone, Stefan Duensing
BACKGROUND: There is mounting evidence to suggest that stromal cells play an integral role in the progression of prostate cancer (PCa). One of the most frequently altered growth factors in PCa is fibroblast growth factor-2 (FGF-2). It has previously been proposed that early stages of PCa are characterized by a primarily exogenous, that is, stromal cell-derived FGF-2 production, whereas advanced tumors rely more on an autocrine FGF-2 production. Prostate cancer progression is characterized by an increase of genomic instability including aneuploidy and structural chromosomal alterations...
June 7, 2018: Urologic Oncology
Timothy D Lyon, Matthew K Tollefson, Paras H Shah, Katherine Bews, Igor Frank, R Jeffrey Karnes, R Houston Thompson, Elizabeth B Habermann, Stephen A Boorjian
PURPOSE: To determine whether the rate of venous thromboembolism (VTE) following radical cystectomy (RC) is changing overtime. MATERIALS AND METHODS: The American College of Surgeons National Surgical Quality Improvement Program database was used to identify patients who underwent RC for bladder cancer from 2011 to 2016. VTE was defined as pulmonary embolism or deep vein thrombosis within 30 days of RC. VTE rate by year was assessed using the Cochran-Armitage test for trend...
June 6, 2018: Urologic Oncology
Alain Kaldany, Kyle A Blum, David J Paulucci, Alp Tuna Beksac, Isuru Jayaratna, John P Sfakianos, Ketan K Badani
INTRODUCTION: Enrollment of a representative study population permits generalizable and reliable results for clinical trials. We sought to evaluate whether patients enrolled in trials for advanced renal cell carcinoma (RCC) are representative of the overall population of advanced RCC patients in the United States. MATERIALS AND METHODS: The results database was queried for interventional clinical trials directed at clinically advanced (stage III/IV) RCC that enrolled patients from the US only...
June 5, 2018: Urologic Oncology
Mihai Dorin Vartolomei, Daniel Porav-Hodade, Matteo Ferro, Romain Mathieu, Mohammad Abufaraj, Beat Foerster, Shoji Kimura, Shahrokh F Shariat
OBJECTIVE: The aim of this study was to summarize and analyze the current evidence regarding the prognostic and predictive value of preoperative neutrophil-to-lymphocyte ratio (NLR) in patients undergoing transurethral resection of bladder tumors (TURBT) for non-muscle-invasive bladder cancer (NMIBC). MATERIAL AND METHODS: A systematic search of Web of Science, Medline/PubMed, Google Scholar, and Cochrane library was performed on the 1st of March, 2018. Studies were deemed eligible if they compared NMIBC patients with high vs...
June 5, 2018: Urologic Oncology
Joanie Pelletier, Sarah-Jeanne Cyr, Anne-Sophie Julien, Yves Fradet, Louis Lacombe, Paul Toren
BACKGROUND: Advanced prostate cancer may cause significant local complications which affect quality of life, including bladder outlet obstruction and hematuria. We performed a detailed review of our outcomes of palliative transurethral resection of the prostate (pTURP) in the era of taxane chemotherapy and potent androgen receptor antagonists at our tertiary-care institution. METHODS: Using hospital coding data, we identified patients with a diagnosis of prostate cancer who underwent a TURP at Hotel-Dieu Hospital in Quebec City between 2006 and 2016 for detailed chart review...
June 4, 2018: Urologic Oncology
Elisabeth E Fransen van de Putte, Wolfgang Otto, Arndt Hartmann, Simone Bertz, Roman Mayr, Johannes Bründl, Johannes Breyer, Quentin Manach, Eva M Compérat, Joost L Boormans, Judith Bosschieter, Michael A S Jewett, Robert Stoehr, Geert J L H van Leenders, Jakko A Nieuwenhuijzen, Alexandre R Zlotta, Kees Hendricksen, Morgan Rouprêt, Maximilian Burger, Theo H van der Kwast, Bas W G van Rhijn
BACKGROUND: Reliable prognosticators for T1 bladder cancer (T1BC) are urgently needed. OBJECTIVE: To compare the prognostic value of 2 substage systems for T1BC in patients treated by transurethral resection (TUR) and adjuvant bacillus Calmette-Guérin therapy. DESIGN, SETTING, AND PARTICIPANTS: The slides of 601 primary T1BCs from four institutes were reviewed by 2 uropathologists and substaged according to 2 classifications: metric substage according to T1 microinvasive (T1m-lamina propria invasion <0...
June 4, 2018: Urologic Oncology
D E Thomas, H Z Kaimakliotis, K R Rice, J A Pereira, P Johnston, M L Moore, A Reed, D M Cregar, C Franklin, R L Loman, M O Koch, R Bihrle, R S Foster, T A Masterson, T A Gardner, C P Sundaram, C R Powell, Sdw Beck, D J Grignon, L Cheng, C Albany, N M Hahn
BACKGROUND: Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated with neoadjuvant chemotherapy (NAC) is uncertain. We assessed the effect of CIS found in pretreatment transurethral resection of bladder tumor (TURBT) biopsies on the pathologic and clinical outcomes. MATERIALS AND METHODS: Subjects with MIUC treated with NAC before cystectomy were identified. The pathologic complete response (pCR) rates stratified by TURBT CIS status were compared...
June 4, 2018: Urologic Oncology
Cosimo De Nunzio, Riccardo Lombardo, Giorgia Tema, Hassan Alkhatatbeh, Giorgio Gandaglia, Alberto Briganti, Andrea Tubaro
OBJECTIVES: The aim of our study was to analyze the performance of 5 different risk calculators for prostate cancer diagnosis: Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC), European Randomized Study of Screening for Prostate Cancer Risk Calculator (ERSP-RC), Karakiewicz nomogram, Chun nomogram, and Kawakami Nomogram. METHODS: From 2008 onwards, we consecutively enrolled, at a single institution in Italy, men undergoing 12-core transrectal ultrasound-guided prostate needle biopsy...
June 4, 2018: Urologic Oncology
A Soave, S Riethdorf, R Dahlem, S Minner, L Weisbach, O Engel, M Fisch, K Pantel, M Rink
OBJECTIVES: To investigate for the presence of circulating tumor cells (CTC) in patients with variant urothelial carcinoma of the bladder (UCB) histology treated with radical cystectomy (RC), and to determine their impact on oncological outcomes. PATIENTS AND METHODS: We, prospectively, collected data of 188 patients with UCB treated with RC without neoadjuvant chemotherapy. Pathological specimens were meticulously reviewed for pure and variant UCB histology. Preoperatively collected blood samples (7...
June 4, 2018: Urologic Oncology
Sangjun Yoo, Dalsan You, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn, In Gab Jeong
PURPOSE: We evaluated the changes in the incidence of benign lesions in surgically removed small renal masses (SRMs) and the effect of diagnostic tests for characterizing SRMs. METHODS: We included 2,707 patients receiving surgery for SRMs (<4cm). Trends in the incidence of benign histology were evaluated according to the surgery year (period 1: 2001-2005, 2: 2006-2010, and 3: 2011-2015). Multivariable logistic regression analysis was performed to identify factors associated with benign lesions...
June 1, 2018: Urologic Oncology
Siamak Daneshmand, Soroush T Bazargani, Trinity J Bivalacqua, Jeffrey M Holzbeierlein, Brian Willard, Jennifer M Taylor, Joseph C Liao, Kamal Pohar, James Tierney, Badrinath Konety
INTRODUCTION: Blue light cystoscopy (BLC) using hexaminolevulinate (HAL/Cysview/Hexvix) has been previously shown to improve detection of non-muscle-invasive bladder cancer (NMIBC). Herein, we evaluated the detection of malignant lesions in a heterogenous group of patients in the real world setting and documented the change in risk category due to upstaging or upgrading. METHODS: Prospective enrollment during April 2014 to December 2016 of consecutive adult patients with suspected or known non-muscle-invasive bladder cancer based on prior cystoscopy or imaging, undergoing transurethral resection of bladder tumor at 9 different referral medical centers...
May 30, 2018: Urologic Oncology
Karim Marzouk, Amy Tin, Nick Liu, Daniel Sjoberg, Abraham Ari Hakimi, Paul Russo, Jonathan Coleman
PURPOSE: The safety and feasibility of active surveillance in comorbid patients with renal masses ≥4.0cm is uncertain. The aim of this study is to describe our institutional experience with the observation of large renal masses. MATERIALS AND METHODS: One hundred patients were identified with renal masses ≥ 4.0cm that were followed on observation for at least 6 months without surgical intervention between 1994 and 2016. Linear regression was conducted to determine predictors for renal mass growth and competing risk methods were used to estimate the probability of progression in the setting of death from other causes...
May 28, 2018: Urologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"